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Lower gut microbiome diversity and higher abundance of 
proinflammatory genus Collinsella are associated with 
biopsy-proven non-alcoholic steatohepatitis  
There is increasing evidence for the role of gut microbial composition in the 
pathogenesis of non-alcoholic fatty liver disease (NAFLD). Non-alcoholic 
steatohepatitis (NASH) is the most serious form of NAFLD where inflammation 
causes liver damage that can progress to cirrhosis. We have characterized the gut 
microbiome composition in UK patients with biopsy-proven NASH (n=65) and 
compared it to that in healthy controls (n=76). We report a 7% lower Shannon 
alpha diversity in NASH patients without cirrhosis (n=40) compared to controls 
(p=2.7x10-4) and a 14% drop in NASH patients with cirrhosis (n=25, p=5.0x10-4). 
Beta diversity (Unweighted UniFrac distance) was also significantly reduced in 
both NASH (p=5.6x10-25) and NASH-cirrhosis (p=8.1x10-7) groups. The genus 
most strongly associated with NASH in this study was Collinsella (0.29% 
abundance in controls, 3.45% in NASH without cirrhosis (False Discovery Rate 
(FDR) p=0.008), and 4.38% in NASH with cirrhosis (FDR p=0.02)). This genus, 
which has been linked previously to obesity and atherosclerosis, was also 
positively correlated with fasting levels of triglycerides (p=0.01) and total 
cholesterol (p=1.2x10-4) and negatively correlated with high-density lipoprotein 
cholesterol (p=2.8x10-6) suggesting that some of the pathways present in this 
microbial genus may influence lipid metabolism in the host. In patients we also 
found decreased abundance of some of the Ruminococcaceae which are known to 
produce high levels of short chain fatty acids which can lower inflammation. This 
may thus contribute to pathology associated with NASH. 











Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease 
worldwide1–3 and includes a spectrum of pathologies ranging from simple steatosis 
through non-alcoholic steatohepatitis (NASH), characterised by the presence of 
inflammation, to cirrhosis4 which is responsible for 2% of all deaths worldwide5. 
Around one-third of those with early NASH will progress to advanced fibrosis and 
cirrhosis within 5-10 years6, but a lack of early symptoms means that patients 
accumulate significant, sometimes irreversible liver damage by the time they are 
diagnosed. Therefore, understanding of contributing factors with potential as 
interventional treatment targets, is urgently sought. 
 
There is a growing body of evidence linking the gut-liver axis to the 
development of NAFLD. NAFLD has been associated with an increase in intestinal 
permeability7, and the subsequent infiltration of Gram-negative bacteria could induce 
liver inflammation via TLR4 signalling, enabling the release of TNF-α and the 
activation of hepatic stellate cells8. As the liver is linked to the intestine through the 
portal circulation, gut-derived products including both nutrients from the diet and 
microbial components will arrive first at the liver9. Pathogenic interactions between the 
liver and microbiota range from straightforward effects, such as increased intestinal 
permeability leading to passage of Gram-negative bacteria into the portal circulation 
and subsequent inflammation10, to more complex interactions with metabolites 
produced by the microbiota, under the influence of modifiable factors such as diet. 
Since the establishment of a gut microbiome characteristic of obesity11, similar links 




Small-scale studies of the microbiome in NASH have been somewhat 
contradictory: a study in 16 NASH patients identified a number of associated genera 
(Parabacteroides and Allisonella), and a longitudinal study has correlated a reduction of 
intrahepatic triglycerides with a reduction in Firmicutes and increase in Bacteroidetes12. 
This has been confirmed in a separate study using real-time PCR for 16S rRNA which 
also associated a drop in Bacteroidetes (in which Prevotella was used as a marker for 
the entire phylum) with NASH13. However, an increase in Bacteroidetes abundance was 
subsequently described in NASH patients14.  
 
Lower alpha diversity has consistently been found to be correlated with obesity 
and insulin resistance15, higher visceral fat16, and a number of inflammatory 
conditions17,18. Since inflammatory processes drive the pathology and progression of 
NAFLD and are linked to features of the metabolic syndrome including insulin 
resistance and visceral fat, we hypothesized that patients with NASH will display 
distinct changes in their microbiota and lower alpha diversity after adjustment for 
possible confounders such as BMI. 
 
We describe significant differences in the microbiome in a substantial, well-
phenotyped cohort of 65 biopsy-proven NASH patients compared to a control cohort of 










The descriptive characteristics of NASH patients and controls are presented in 
Table 1. The healthy control group was slightly older on average compared to the 
NASH group, and was predominantly females. The control group had a significantly 
lower median BMI compared to the NASH group, therefore all analyses were adjusted 
for age, sex and BMI. All participants in the control group were of White ethnicity; 87% 
(33/40 NASH and 24/25 NASH-cirrhosis) of the patients were of White ethnicity. No 
significant differences in demographics were observed between NASH and NASH-
cirrhosis groups. Within the NASH group, 1 patient had no fibrosis, 8 patients had 
fibrosis grade F1, 8 had grade F2, and 23 had grade F3. 
 
Diversity metrics 
A significant decrease in alpha diversity, indicated by Shannon index and 
operational taxonomic units (OTUs), was observed in both NASH and NASH-cirrhosis 
groups compared to controls (all p<0.05;Table 1; Figure 1). A significant decrease in 
beta diversity (Unweighted UniFrac), indicative of inter-individual diversity, was also 
observed between control and NASH groups, although it was slightly higher in the 
NASH-cirrhosis group compared to the NASH group (Figure 1). 
 
OTUs significantly associated with NASH 
Of the 124 OTUs used in the analysis, 27 were significantly associated with 
NASH after adjustment for covariates (age, gender and BMI) and false discovery rate 
(FDR), and 21 of these remained significant in the NASH-cirrhosis group. Several 
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OTUs were significantly associated with a higher likelihood of NASH: most 
significantly Collinsella, which was also significantly associated with the cirrhosis 
group (Figures 2 and 3). These OTUs remained associated when patients with white 
ethnicity only were analysed (data not shown).The genera most significantly associated 
with the control group relative to NASH were Clostridium sensu stricto 1, an 
unidentified genus belonging to the order Mollicutes RF9, Alistipes and several 
Ruminococcaceae (Figures 2 and 3). 
 
Figure 4 displays the relative abundance of each OTU significantly associated 
with presence of NASH. Collinsella showed a 12-fold increase in relative abundance in 
the NASH group, increasing from 0.29% to 3.44%, and to 4.38% in NASH-cirrhosis 
patients. Conversely, the genera Allistipes, Peptoclostridium, Paraprevotella and two 
Ruminococcaceae showed statistically significant reductions in the both NASH groups 
relative to controls.  
 
A number of genera had significantly reduced abundance in NASH-only 
participants. However, of these, Actinomyces, Fusicatenibacter, an unknnown 
Lachnospiracae, an unknown Mollicutes RF9, Paraprevotella and Ruminococcaceae 
UCG-010 were not significantly altered in the cirrhosis group compared to controls. 
Aside from Mollicutes RF9, which had a similar relative abundance in the NASH-
cirrhosis group to in controls, the remaining 5 genera all displayed similar changes in 





Microbial associations with dietary components  
We then assessed the link between nutrient intake and the abundance of taxa to 
investigate the potential impact of diet on microbes which could contribute to the 
development of NASH/NASH-cirrhosis. Figure 5 shows a heatmap summarizing 
Spearman correlations between nutrient intake calculated from a Food Frequency 
Questionnaire (FFQ) and the bacterial genera found to be associated with presence of 
NASH. The genera that showed significantly positive associations with fibre (NSP) 
were Eggerthella (r=0.646; p=0.047) and Ruminococcaceae UCG-014 (r=0.853; p 
=0.003), whereas Collinsella (r =–0.785; p=0.015) showed a negative correlation. 
Collinsella showed a positive correlation (r=0.647; p=0.051) with total fat although it 
did not reach statistical significance, whereas Alistipes and Eggerthella were 
significantly correlated with fat intake (r=-0.517; p =0.040 and r=-0.717; p=0.033, 
respectively). The correlation between Collinsella and sugar was r=0.512 (p=0.062) and 
the correlation with total carbohydrates was r=0.326 (p=0.822). 
Serum lipids 
Based on our finding that the abundance of Collinsella is 12-fold higher in 
NASH patients and correlation with fat intake, we explored the association between 
Collinsella and circulating lipid sub-types to investigate any changes in fat metabolism 
that may arise which impact on disease pathways (Table 2). Fasting serum levels of 
triglycerides (TG), and saturated fatty acids were significantly higher in the NASH and 
NASH-cirrhosis group than in controls (Supplementary Table 1) whereas levels of low 
density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-
C) were lower in patients. Correlation between these lipids and presence or absence of 
NASH/NASH-cirrhosis was then assessed (Supplementary Table 2). HDL-C was the 
most strongly associated lipid with NAFLD showing a strong negative correlation 
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(Pearson’s r= -0.75 p=1.9x10-17), TG and LDL-C and fatty acids were also correlated 
with presence of disease.  
 
We then tested whether any of these markers were also correlated with the 
abundance of the genus Collinsella (Table 2) and found that HDL-C was inversely 
associated with its abundance (r=-0.39, p=2.8x10-6). A significant positive correlation 
was seen between the relative abundance of Collinsella and both serum TG (r=0.21, 



























Links between the microbiome and the development of NAFLD are now well 
established19,20, but the details of changes in specific genera is lacking. We aimed to 
compare a substantial cohort of biopsy-proven NASH and NASH-cirrhosis patients, 
with a well characterised control cohort sourced from the TwinsUK study. 
 
The genus most strongly associated with NASH in this study, Collinsella, has 
been previously linked to obesity and atherosclerosis in human studies21–23, showing a 
4-fold increase in abundance in obesity and 3.5-fold in type 2 diabetes24. It has also 
been found to be highly abundant in untreated patients with hypercholesterolaemia 
compared to controls and patients treated with statins25. NMR spectroscopy in a mouse 
model has shown a significant correlation between members of the Coriobacteriaceae 
family, which includes Collinsella, and hepatic triglycerides26. Collinsella has been 
linked to pro-inflammatory dysbiosis in type 2 diabetes24 and with circulating insulin21, 
suggestive of a mechanism for promotion of NAFLD pathology.  
 
Insulin resistance and dyslipidaemia are characteristic of NAFLD27,28. 
Consistent with this, we show significant increases in total triglycerides, VLDL-C and 
saturated fatty acids, and concomitant reduction in HDL-C in both NASH and NASH-
cirrhosis groups. We also report that the abundance of Collinsella is negatively 
correlated with serum HDL-C levels and positively correlated with TG, which suggests 
that some of the pathways present in this microbial genus may influence lipid 
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metabolism in the host. This is consistent with previous work in healthy adults 
correlating Collinsella abundance with total cholesterol29, and in agreement with animal 
studies26,30. We observed a significant inverse correlation between the relative 
abundance of Collinsella and dietary fibre (Figure 5) as previously reported in obese 
women21. Dietary fibre and the gut derived metabolites that are associated with its 
breakdown (i.e. short chain fatty acids) have been implicated in the aetiology of 
metabolic disease including NAFLD31. Increasing dietary fibre intake could be 
considered a strategy for modulating the composition of the gut microbiome32, reducing 
dysbiosis with the potential to reduce pathological features.   
 
Collinsella spp. have been shown to metabolise bile acids to oxo-bile acid 
intermediates. Production of these secondary bile acids may increase intestinal 
permeability and contribute to the development of NAFLD33,34. Administration of the 
antibiotic rifaximin to decrease 7α-dehydroxylating bacteria (including Collinsella) has 
been linked to a drop in secondary fecal bile acid concentrations35. This provides a 
convincing mechanism by which Collinsella could mediate the progression of NAFLD, 
but further work is required to establish this link and determine the specific species or 
group of species that could be the cause. 
 
We identified an OTU belonging to the putative order Mollicutes RF9 
significantly associated with the control cohort. Members of the Mollicutes class have 
previously been linked to obesity36, but their functional roles are unclear37. Recent 
work38 has correlated abundance of Mollicutes RF39 with circulating indolepropionic 
acid, a potent antioxidant produced by the microbiota and associated with a lower risk 




Several genera belonging to the order Clostridiales were also associated with the 
control group in this study. Of these, we found that Ruminococcaceae showed 
significant positive correlations with fibre intake. Several Ruminococcaceae have 
previously been inversely associated with cirrhosis in small studies including patients 
with a variety of aetiologies41,42, and with NAFLD43,44. Ruminococcaceae are mainly 
responsible for fermenting fibre and other plant components of the diet such as inulin 
and cellulose, producing short-chain fatty acids (SCFA) which can both be utilised by 
the host for energy45, and display anti-inflammatory properties in the gut46.  
 
We report a lower alpha diversity in NASH patients, further reduced in those 
with cirrhosis, similar to previous work comparing NAFLD patients without advanced 
fibrosis to those with cirrhosis 47. We also demonstrate parallel changes in beta 
diversity, with a decline in our 40 NASH patients (of which 23 had advanced fibrosis) 
compared to controls but with no further reduction in cirrhotics. This indicates that the 
microbiome in the general population is both more diverse and more stable than that of 
both NASH and NASH-cirrhosis patients, with inter-individual variation increasing in 
cirrhosis. In agreement with earlier publications, we found a notable decrease in 
Bacteroides abundance in both the NASH group and NASH-cirrhosis groups. Unlike a 
previous report in paediatric NAFLD48, we did not see a significant decrease in 
Oscillspira; increases in Blautia and Ruminococcus were observed but did not achieve 
statistical significance. Increases in Blautia and Ruminococcus were similarly observed 
in a cirrhosis group in the aforementioned Caussy et al. study47, but not in their cohort 
without advanced fibrosis. This suggests that some of these changes may reflect 
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different stages of severity of liver disease and highlights the importance of in-depth 
hepatic phenotyping. 
 
We acknowledge several limitations in our study. The control group is 
predominantly female whereas both NASH and cirrhosis groups are more evenly gender 
balanced. The effect of gender on the microbiome is well established49,50 and may 
therefore have some effect on our results, but this has been adjusted for in all statistical 
comparisons. There are also acknowledged issues with using 16S reads as a proxy 
indicator for abundance51 compared to absolute quantification with genus or species-
specific PCR primers or a metagenomic sequencing approach. The study presented here 
is also purely observational; a germ-free animal model would be required to definitively 
verify the links we propose between Collinsella abundance, NASH and lipid 
metabolism. Furthermore, the associations between nutrients and the gut microbiome 
would require further evaluations to explore their interdependence in the aetiology of 
NASH and NASH-cirrhosis. The diet-gut microbiome associations presented are based 
on statistical associations from cross-sectional observations, and do not prove that 
causal relationships exist. Further explorations into causal impacts would require dietary 
interventions. In order to untangle the effect of nutrients on host-microbiome crosstalk, 
future studies should also consider looking at fecal metabolites such as SCFAs. Fecal 
bile acid data was also not available for this study; this would be required to study the 
metabolic effects of Collinsella in more detail, as well as the gut-liver axis in general52. 
Thus, our study could be improved by looking at bacterial metabolic responses to diet 
which may be more informative in assessing the effect of certain nutrients on health, 




Overall, we have determined the relationship between gut microbiome 
composition and diversity and disease in the largest biopsy-proven NASH cohort to 
date. We confirm the findings from previous studies14,47 showing a reduced alpha 
diversity in NASH patients and further decrease in cirrhosis patients. We also report, for 
the first time, that the genus Collinsella is significantly increased in NASH patients with 
and without cirrhosis. This association with pathology is suggested to be linked with 
effects on host lipid metabolism and diet. 
 
Materials and methods 
Study participants 
The 65 adult patients included in this study were prospectively recruited from 
hepatology clinics at Nottingham University Hospitals NHS Trust. Patients gave 
informed consent to participate in research studies in accordance with the 1975 
Declaration of Helsinki. The studies were approved by NHS Regional Ethics 
Committees (REC reference 12/WM/0288 and GM010201). NASH was diagnosed on 
the basis of the following criteria: appropriate exclusion of other causes of liver disease 
including alcohol, drugs, autoimmune or viral hepatitis, or cholestatic or 
metabolic/genetic liver disease; a weekly ethanol consumption of <140g in women and 
<210g in men and a liver biopsy showing steatohepatitis with or without cirrhosis. The 
Fatty Liver Inhibition of Progression (FLIP) Consortium algorithm was used as a 
diagnostic indicator where histological diagnosis of NASH requires presence of 
steatosis, ballooning and lobular inflammation, and those without all three features are 
identified as having fatty liver while those lacking steatosis (<5% hepatocytes with fat 
accumulation) are not considered as having NASH53. Fibrosis was scored following the 
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CRN grading system54 by a single pathologist. Patients were stratified into two groups: 
NASH (40 patients without cirrhosis) and NASH with cirrhosis (25 patients). All 
patients in the NASH-cirrhosis group had compensated cirrhosis at the time of sample 
collection. 
76 healthy controls were included from the UK Adult Twin Registry 
(TwinsUK), a large cohort of volunteer adult twins from the United Kingdom hosted by 
the Department of Twin Research and Genetic Epidemiology at St. Thomas’ Hospital, 
King’s College London 55.This cohort contained 13 twin pairs (9 monozygotic pairs and 
4 dizygotic pairs); all others had a twin who was not included. 
Sequencing 
Fecal samples were provided at study visits and immediately frozen at -80C. 
DNA was extracted by homogenising in lysis buffer (500mM NaCl, 50mM Tris-HCl, 
50mM EDTA, 4% SDS) with bead beating (MagNA Lyser, Roche) followed by 
extraction using the QIAmp DNA Stool Mini Kit (Qiagen; cat 51504). DNA was 
diluted to 20ng/µl for 16S rRNA amplification and sequencing at the Genetic 
Laboratory, Erasmus Medical Center, Rotterdam, the Netherlands. Water negative 
controls were included from extraction, through PCR to sequencing and select samples 
were sequenced in duplicate for quality control. 
 
The V4 region of the 16S ribosomal RNA gene was amplified using universal 
primers 355F (CCAGACTCCTACGGGAGGCAGC) and 806R 
(GGACTACHVGGGTWTCTAAT). Amplified DNA was sequenced on the MiSeq 
platform (Illumina). Read filtering and clustering was carried out using the MYcrobiota 
pipeline56. Briefly, chimeric sequences were filtered using the VSEARCH algorithm 
within Mothur, and reads were clustered into operational taxonomic units (OTUs) using 
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closed-reference clustering against the SILVA database v132 based on a 97% similarity. 
Diversity metrics (Shannon index, observed OTUs and Unweighted UniFrac) were 
calculated by rarefying the OTU table down to 7000 sequences per sample 50 times and 
taking the average. These analyses were carried out in QIIME 2 (v2018.11). 
Lipid measurements 
Serum lipids were quantified using a high-throughput 1H NMR platform 
(Nightingale Health, Helsinki, Finland) using 500Mhz and 600MhH protein nuclear 
magnetic resonance spectroscopy as described previously57,58. 
Diet-microbiome analysis 
Self-reported dietary intake was assessed by food frequency questionnaires 
following the EPIC-Norfolk guidelines59. Individuals answered questions on intake of 
131 food groups and nutrient intakes (weight/day) were derived from the UK Nutrient 
Database using the FETA software (version 2)60. A total of thirty-three nutrients were 
estimated from this calculation. Associations between relative abundances of bacterial 
taxa shown to be significantly associated with NASH or the control group, and nutrient 
intakes (adjusted for total energy (kcal)) intake were examined by Spearman 
correlation. 
Statistical analysis 
OTUs with a relative abundance of <0.1% in every sample were removed, and 
relative OTU abundances were inverse normal transformed before further analysis. 
Associations between NASH and NASH-cirrhosis groups and OTU abundance at genus 
level were predicted using a general linear model adjusted for age, gender and BMI. 
OTUs were assumed to be significantly associated with NASH or cirrhosis with a p 
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Figure 1: Diversity metrics in control, NASH and NASH-cirrhosis groups. A: Alpha 
diversity measured using the Shannon index, B: Beta diversity measured using 
Unweighted UniFrac distances between all samples in each group. Diversity indicies 
were calculated using the OTU table rarefied to 7000 sequences per sample 50 times 





Figure 2: Heat map showing all OTUs (clustered at genus level) significantly 
associated with NASH or the control group and association with presence of NASH, 
NASH-cirrhosis, BMI, hypertension, total fasted triglycerides (TG), high density 
lipoprotein (HDL), low density lipoprotein (LDL) and fasted glucose. Values are beta 
coefficients from linear models adjusted for BMI, age and gender (associations between 
genera and BMI are adjusted for age and gender only). P values shown in parentheses 




Figure 3: Forest plot of effect sizes with 95% confidence intervals showing association 
of all significant (FDR adjusted p <0.05) OTUs with NASH and NASH-cirrhosis 






Figure 4: Relative abundance of all OTUs significantly associated (FDR p<0.05) with 
the NASH group. *p<0.05, **p<0.01. 
 
 
Figure 5: Heatmap depicting the correlation between the abundance of genera 
significantly associated with NASH and NASH-cirrhosis and dietary components. The 
intensity of the colour represents the degree of association between bacterial 
abundances and nutrients as measured by Spearman’s correlations. The asterisk symbols 





Table 1: Characteristics of the study population.  






Sex (female/male) 67/9 20/20 15/10 
Mean age 
(mean±SEM) 
66.3±1.06  60.3±1.6a 64.0±2.0 
Mean BMI (kg/m2, 
mean±SEM) 
26.5±0.5 34.9±1.1a 34.0±1.1b 
Type 2 Diabetes 0 22a 19b 
Hypertension 1 19a 14b 
Shannon diversity 
(mean±SEM) 
5.83±0.1 5.32±0.1a 5.18±0.2b 
Observed OTUs 
(mean±SEM) 
405.3±10.9 334.8±9.5a 313.7±16.9b 
NASH: non-alcoholic steatohepatitis; SEM: standard error of the mean; OTUs: 
operational taxonomic unit.ap<0.05 Healthy vs NASH, bp<0.05, Healthy vs NASH-
cirrhosis, cp<0.05 NASH vs NASH-cirrhosis, ANOVA with a priori contrasts or 





Table 2: Correlation between relative abundance of Collinsella and serum lipids in the 














VLDL-C:very low density cholesterol;HDL-C: high density lipoprotein cholesterol; 
LDL-C: low density lipoprotein cholesterol. 
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